Pro-oncogene Pokemon promotes breast cancer progression by upregulating survivin expression

Breast Cancer Research

Volumn 13, Issue 2, 2011, Pages

  Zu, Xuyu ^a,b   Ma, Jun ^c   Liu, Hongxia ^a   Liu, Feng ^a   Tan, Chunyan ^a   Yu, Lingling ^a   Wang, Jue ^a   Xie, Zhenhua ^a   Cao, Deliang ^c   Jiang, Yuyang ^a,d  

^a TSINGHUA UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR POKEMON; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; DNA BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER; TUMOR PROTEIN; ZBTB7A PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; SITE DIRECTED MUTAGENESIS; TISSUE MICROARRAY; TUMOR VOLUME; APOPTOSIS; BIOSYNTHESIS; BREAST TUMOR; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHATIC METASTASIS; MUTAGENESIS, SITE-DIRECTED; NEOPLASM PROTEINS; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860389046     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2843     Document Type: Article

References (42)

1. Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 2005, 433:278-285. 10.1038/nature03203, 15662416.
2. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006, 124:207-219. 10.1016/j.cell.2005.10.043, 16413492.
3. Apostolopoulou K, Pateras IS, Evangelou K, Tsantoulis PK, Liontos M, Kittas C, Tiniakos DG, Kotsinas A, Cordon-Cardo C, Gorgoulis VG. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. J Pathol 2007, 213:294-302. 10.1002/path.2222, 17907153.
4. Aggarwal A, Hunter WJ, Aggarwal H, Silva ED, Davey MS, Murphy RF, Agrawal DK. Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers. Exp Mol Pathol 2010, 89:140-148. 10.1016/j.yexmp.2010.05.002, 20471975.
5. Laudes M, Bilkovski R, Oberhauser F, Droste A, Gomolka M, Leeser U, Udelhoven M, Krone W. Transcription factor FBI-1 acts as a dual regulator in adipogenesis by coordinated regulation of cyclin-A and E2F-4. J Mol Med 2008, 86:597-608. 10.1007/s00109-008-0326-2, 18368381.
6. Pendergrast PS, Wang C, Hernandez N, Huang S. FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles. Mol Biol Cell 2002, 13:915-929. 10.1091/mbc.01-08-0383, 99609, 11907272.
7. Kukita A, Kukita T, Ouchida M, Maeda H, Yatsuki H, Kohashi O. Osteoclast-derived zinc finger (OCZF) protein with POZ domain, a possible transcriptional repressor, is involved in osteoclastogenesis. Blood 1999, 94:1987-1997.
8. Choi WI, Jeon BN, Park H, Yoo JY, Kim YS, Koh DI, Kim MH, Kim YR, Lee CE, Kim KS, Osborne TF, Hur MW. Proto-oncogene FBI-1 (Pokemon) and SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). J Biol Chem 2008, 283:29341-29354. 10.1074/jbc.M802477200, 2662021, 18682402.
9. Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J, van den Brink MR, Zelent A, Shigematsu H, Akashi K, Teruya-Feldstein J, Cattoretti G, Pandolfi PP. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science 2007, 316:860-866. 10.1126/science.1140881, 2978506, 17495164.
10. Maeda T, Hobbs RM, Pandolfi PP. The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res 2005, 65:8575-8578. 10.1158/0008-5472.CAN-05-1055, 16204018.
11. Lee DK, Suh D, Edenberg HJ, Hur MW. POZ domain transcription factor, FBI-1, represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity of Sp1. J Biol Chem 2002, 277:26761-26768. 10.1074/jbc.M202078200, 12004059.
12. Lee DK, Kang JE, Park HJ, Kim MH, Yim TH, Kim JM, Heo MK, Kim KY, Kwon HJ, Hur MW. FBI-1 enhances transcription of the nuclear factor-κB (NF-κB)-responsive E-selectin gene by nuclear localization of the p65 subunit of NF-κB. J Biol Chem 2005, 280:27783-27791. 10.1074/jbc.M504909200, 15917220.
13. Jeon BN, Yoo JY, Choi WI, Lee CE, Yoon HG, Hur MW. Proto-oncogene FBI-1 (Pokemon/ZBTB7A) represses transcription of the tumor suppressor Rb gene via binding competition with Sp1 and recruitment of co-repressors. J Biol Chem 2008, 283:33199-33210. 10.1074/jbc.M802935200, 2662252, 18801742.
14. Widom RL, Lee JY, Joseph C, Gordon-Froome I, Korn JH. The hcKrox gene family regulates multiple extracellular matrix genes. Matrix Biol 2001, 20:451-462. 10.1016/S0945-053X(01)00167-6, 11691585.
15. Pessler F, Hernandez N. Flexible DNA binding of the BTB/POZ-domain protein FBI-1. J Biol Chem 2003, 278:29327-29335. 10.1074/jbc.M302980200, 12750370.
16. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921. 10.1038/nm0897-917, 9256286.
17. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rödel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65:4881-4887.
18. Li F. Survivin study: what is the next wave?. J Cell Physiol 2003, 197:8-29. 10.1002/jcp.10327, 12942537.
19. Grabowski P, Kühnel T, Mühr-Wilkenshoff F, Heine B, Stein H, Höpfner M, Germer CT, Scherübl H. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003, 88:115-119. 10.1038/sj.bjc.6600696, 2376783, 12556969.
20. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000, 96:1921-1925.
21. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer 2003, 88:1077-1083. 10.1038/sj.bjc.6600776, 2376388, 12671708.
22. Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999, 17:2100-2104.
23. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998, 58:5071-5074.
24. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623. 10.1038/sj.onc.1203358, 10698506.
25. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 2003, 97:1077-1083. 10.1002/cncr.11122, 12569609.
26. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005, 65:11018-11025. 10.1158/0008-5472.CAN-05-0491, 16322251.
27. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277:3247-3257. 10.1074/jbc.M106643200, 11714700.
28. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21:2613-2622. 10.1038/sj.onc.1205353, 11965534.
29. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002, 303:124-131. 10.1124/jpet.102.037192, 12235242.
30. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999, 344:305-311. 10.1042/0264-6021:3440305, 1220645, 10567210.
31. Siddiqui SF, Pawelek J, Handerson T, Lin CY, Dickson RB, Rimm DL, Camp RL. Coexpression of β1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome. Cancer Epidemiol Biomarkers Prev 2005, 14:2517-2523. 10.1158/1055-9965.EPI-05-0464, 16284372.
32. Giltnane JM, Moeder CB, Camp RL, Rimm DL. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 2009, 115:2400-2409. 10.1002/cncr.24277, 2756449, 19330842.
33. Yan R, Zu X, Ma J, Liu Z, Adeyanju M, Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int J Cancer 2007, 121:2301-2306. 10.1002/ijc.22933, 17597105.
34. Zu X, Yan R, Robbins S, Krishack PA, Liao DF, Cao D. Reduced 293T cell susceptibility to acrolein due to aldose reductase-like-1 protein expression. Toxicol Sci 2007, 97:562-568. 10.1093/toxsci/kfm033, 17329238.
35. Zu X, Yu L, Sun Q, Liu F, Wang J, Xie Z, Wang Y, Xu W, Jiang Y. SP1 enhances Zbtb7A gene expression via direct binding to GC box in HePG2 cells. BMC Res Notes 2009, 2:175. 10.1186/1756-0500-2-175, 2749864, 19723341.
36. Liu Z, Zhong L, Krishack PA, Robbins S, Cao JX, Zhao Y, Chung S, Cao D. Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene 2009, 437:39-44. 10.1016/j.gene.2009.02.007, 2668737, 19236911.
37. Chung SW, Chen YH, Yet SF, Layne MD, Perrella MA. Endotoxin-induced down-regulation of Elk-3 facilitates heme oxygenase-1 induction in macrophages. J Immunol 2006, 176:2414-2420.
38. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
39. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 2009, 15:1326-1334. 10.1158/1078-0432.CCR-08-0954, 2663973, 19228734.
40. Spaulding B, Pan D, Ghadersohi A, Nielsen G, Jensen S, Gellert F, Ling X, Zhang M, Black A, Li F. Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues. Histopathology 2006, 49:622-633. 10.1111/j.1365-2559.2006.02556.x, 2826143, 17163847.
41. Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, Zhou M. KLF5 interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem 2006, 281:14711-14718. 10.1074/jbc.M513810200, 16595680.
42. Agrawal A, Yang J, Murphy RF, Agrawal DK. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. Exp Mol Pathol 2006, 81:115-122. 10.1016/j.yexmp.2006.07.001, 16919268.